|
Mr Peter Francis is a partner at Francis Abourizk Lightowlers (FAL), a firm of commercial and technology lawyers with offices in Melbourne, Australia. He is a legal specialist in the areas of intellectual property and licensing and provides legal advice to a large number of corporations and research bodies. Other Current Directorships of Listed Companies None Former Directorships of Listed Companies in last three years |
 Dr Mel Bridges BAPPSC, FAICD Non-Executive Director Appointed 12 Oct 2007 |
Dr Mel Bridges has more than 30 years’ experience in the global biotechnology and healthcare industry. During this time he founded and managed successful diagnostics, biotechnology and medical device businesses. Mel co-founded listed company Panbio Ltd and he is currently Chairman of Alchemia Ltd. Mel has extensive experience as a public company director and is a Non-Executive Director of ALS Limited, ImpediMed Limited and Tissue Therapies Limited.
The businesses that Mel has founded have won numerous awards including the Queensland Export Award, Australian Small Business of the Year, Queensland Top 400, BRW's Top 100 Fastest Growing Companies for seven consecutive years, and The Australian Quality Award. Mel has won numerous awards for his achievements including the Ernst and Young 2002 Entrepreneur of the Year. In 2004 he was anointed the Queensland Entrepreneur of the Year, and in 2005 industry group AusBiotech awarded him the Chairman’s Industry Gold Medal for contributions to the Australian biotech industry. |
 Dr John Chiplin PH.D. Non-Executive Director Appointed 1 Feb 2010 |
Dr John Chiplin has broad-based experience in the life science and technology industries, both from an operational and investment perspective. His most recent accomplishment was the corporate reengineering of Arana Therapeutics, a world leading Antibody developer, which resulted in the acquisition of the company by Cephalon for a significant premium to market (July 2009). Immediately prior to running Arana, Dr Chiplin was head of the $300M ITI Life Sciences investment fund in the UK. His own investment vehicle, Newstar Ventures Ltd, has funded more than a dozen early stage companies in the past ten years. Dr Chiplin’s Pharmacy and Doctoral degrees are from the University of Nottingham, UK. In addition to Benitec Biopharma, he currently serves on the Boards of Calzada Ltd and ScienceMedia, Inc. Other Current Directorships of Listed Companies Calzada Ltd. Former Directorships of Listed Companies in last three years Arana Therapeutics Ltd, Progen Pharmaceuticals Ltd and Healthlinx Ltd. |
 Mr Iain Ross BSC, CH.D. Non-Executive Director Appointed 1 June 2010 |
Mr Iain Ross is an experienced business man with 30 years’ experience in the international life sciences sector. Following a career with Sandoz, Fisons, Hoffman La Roche, and Celltech he has undertaken and input to a number of company turnarounds and start-ups as a board member on behalf of banks and private equity groups. He has led and participated in 4 IPOs, has direct experience of life science mergers and acquisitions both in the UK and USA and has raised more than £200m in the biotech sector. He is a Qualified Chartered Director and currently he is Chairman of Ark Therapeutics Group plc (LSE); Pharminox Limited; Biomer Technology Limited and a non-executive director of Tissue Therapies Limited (ASX). Also he is Vice Chairman of the Council of Royal Holloway, University of London. Other Current Directorships of Listed Companies Ark Therapeutics Group plc, Tissue Therapies Limited. Former Directorships of Listed Companies in last three years Silence Therapeutics plc. |
 Mr J. Kevin Buchi BA (Chem), MIM Non-Executive Director Appointed April 2013 |
Mr J. Kevin Buchi has extensive experience serving on the boards of biopharmaceutical and pharmaceutical companies in the USA and Europe. As CEO of Cephalon in 2011, he led the company through its $6.8 billion acquisition by Teva Pharmaceutical Industries and later served as Corporate Vice President, Global Branded Products of Teva. Having joined Cephalon in 1991, he held several senior positions including Chief Operating Officer, Chief Financial Officer and Head of Business Development prior to being appointed CEO. Mr. Buchi is a Certified Public Accountant, originally training as a synthetic organic chemist for the Eastman Kodak Company. He graduated from Cornell University with a Bachelor of Arts degree in chemistry, he holds Master’s Degree in Management from the Kellogg Graduate School of Management at Northwestern University, and resides in Pennsylvania in the United States. Other Current Directorships of Listed Companies Stemline Therapeutics, Inc and Alexza Pharmaceuticals. Former Directorships of Listed Companies in last three years |
